TeamDrive
RUS

Interdepartmental Commission has approved NovaMedicas application for conclusion of SPIC aimed at creation of a new pharmaceutical manufacturing facility

22 December 2017

Moscow, December 22, 2017 – Russian pharmaceutical company NovaMedica (investment project of Rusnano) informed that it received approval of the Interdepartmental Committee (IDC) to conclude the Special Investment Contract (SPIC) within the investment project devoted to creation of a pharmaceutical plant for manufacturing of sterile injectable drug products in the Kaluga region. This is the first SPIC in the industry which is aimed at support of creation of a greenfield pharmaceutical facility. 

Portfolio of drug products which was supported by the IDC includes essential drugs which were transferred to NovaMedica within its partnership with Pfizer as well as own development products of NovaMedica. SPIC envisages extension of this list with the development of the pipeline of own R&D products of NovaMedica subject to approval of the IDC. Company plans to manufacture more than 40 modern effective drug products which are demanded by the Russian patients. 

“Creation of a greenfield high-tech pharmaceutical manufacturing facility in full compliance with international standards of quality will allow us to provide Russian patients with effective drug products and will open an opportunity to export our products abroad. SPIC is highly important for us. We greatly appreciate support of the Ministry of Industry and Trade of the Russian Federation and Administration of the Kaluga region where our plant is going to be constructed as well as of our strategic partner – Pfizer which transfers to us valuable knowledge and technologies of manufacturing of modern highly-demanded drug products”, noted Alexander Kuzin, CEO of NovaMedica

SPIC will include main measures of stimulation of development of pharmaceutical manufacturing in Russia by providing the status of local manufacturer as well as of the right to receive the status of unique supplier of a wide range of essential drug products in order to participate in the process of state procurement. Term of the SPIC is until 2026. It is planned that the Contract will be signed in the next couple of months. 

About NovaMedica

NovaMedica is a modern Russian pharmaceutical company founded in 2012 by Domain Associates LLC, leading U.S. venture capital firm, and RUSNANO, JSC. NovaMedica possesses a well-developed infrastructure for promotion and sales of pharmaceutical products. Currently company is promoting a portfolio of 25 ophthalmological and gastroenterological products in the Russian market. NovaMedica's strategy is aimed at search, registration and localization in Russia of intellectual property rights for innovative pharmaceuticals products and technologies, as well as at development and implementation of own R&D projects. In April 2017 NovaMedica opened the Technological Center with state-of-the-art technological capabilities which were previously unavailable in the Russian pharmaceutical industry. NovaMedica became key partner of Pfizer in Russia in 2016. Within this partnership NovaMedica started construction of the pharmaceutical GMP manufacturing facility in the Kaluga region in May 2017. In October 2017 R&D Center of NovaMedica received a manufacturing license from the Ministry of industry and Trade of the Russian Federation. In December 2017 Interdepartmental Commission approved NovaMedica’s application for SPIC to create new pharmaceutical manufacturing facility in the Kaluga region.

More information at www.novamedica.com, follow us on Facebook and LinkedIn.


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more